KLOW peptide stack.

Why add KPV?

Some people discuss KLOW as a way to pursue the same skin, hair and recovery aims as GLOW, while reducing injection-site reactions or producing a broader anti-inflammatory effect. KPV has been investigated in cells and mice, but that is not a trial of this blend or of injection-site reactions in people. In July 2026, the US FDA reported that it had identified no clinical studies or human exposure data for KPV by any route; human safety risks remain unknown. Reports differ, and we found no controlled human comparison showing that adding KPV prevents a reaction or makes KLOW safer than GLOW. Learn what an injection-site reaction can mean and compare the products and their proposed roles.892

Explore the reasoning and its limits in KPV, gut inflammation and KLOW.

For the proposed role of each ingredient and the evidence behind it, see how GLOW and KLOW are meant to work.

Illustrations

Open image at full size

What KLOW usually means

One published description lists KLOW as GHK-Cu, BPC-157, TB-500 and KPV. This is an example of how the name is used, not an official composition. Amounts, salts, preparation and route may differ. A published ingredient list does not independently confirm a product’s identity, quality or clinical performance. See storage claims, product quality and travel for practical context.1

Why adding an ingredient changes the question

KPV is a short peptide related to an alpha-melanocyte-stimulating hormone fragment, while the other components have different proposed activities. Putting four substances in one vial does not show whether their effects add to or complement each other. It can also create new questions about stability, compatibility, interactions and immune reactions.24

What regulators say about risk

FDA materials identify potential concerns for compounded products containing BPC-157, injectable GHK-Cu and TB-500, including peptide-related impurities, aggregation and immunogenicity. FDA also says it has not identified human exposure data for drug products containing KPV administered by any route. These are safety and evidence limitations, not a finding that every seller's batch has the same defect.23

In the US, a draft policy describes conditions for certain single-ingredient compounded peptide products. A blend with multiple active ingredients does not meet that condition. The policy is not FDA approval; see the US policy section below for its scope and limits.67

If you have already injected a product and the skin is painful, hot and swollen, seek urgent medical advice; these signs can have different causes, including infection. Sudden swelling of the lips, mouth, tongue or throat, or difficulty breathing, needs emergency help immediately. Tell the clinician what you used and, if available, bring its packaging. See injection-site reactions and when to seek help.1011

In a 5 November 2026 advisory, Australia’s TGA reported that testing of Synedica KLOW 80 mg and Synedica BARBIE KLOW 100 mg found no detectable TB-500, despite the labels. The agency also lists vitamin B12 on these products’ labels, illustrating that names do not define one formula. This result concerns the tested products, not every KLOW product. The TGA advises anyone with a Synedica-branded peptide product to stop using it, take remaining product to a local pharmacy for safe disposal in Australia, and speak to a health professional about health concerns.12

The human-evidence gap

A cell study, animal study or human study of one ingredient cannot establish the effects of the KLOW combination. To answer the blend question, researchers would need a defined formulation, reproducible manufacturing, a suitable comparator and enough follow-up to measure benefits and harms. Testimonials and certificates of analysis do not replace that trial evidence.45

A reader's checklist

Ask which ingredients the specific product contains and whether that exact product has been tested in people; whether the source provides independent identity, purity, potency and sterility testing; whether the route is authorised in your country; and whether the claimed outcome was measured against a meaningful comparison. If those answers are missing, describe KLOW as an unstandardised marketed blend with uncertain benefits and risks.25

U.S. compounding policy: a narrow interim position

This US draft policy concerns certain single-ingredient compounded products. It does not approve this blend or establish that it is safe or effective.

In October 2026 HHS published a draft interim enforcement-discretion policy covering specified forms of BPC-157, TB-500, KPV, epitalon, MOTS-c and Semax in section 503A compounding. GHK-Cu is not among the substances listed in Appendix A. Appendix B identifies the chemical form and routes addressed for each listed peptide; the policy also describes conditions including a patient-specific prescription, ingredient characterization and a single active ingredient. It is a statement of enforcement intent, not FDA approval or proof of safety or effectiveness; it does not establish the legality or quality of an online vial or a multi-ingredient stack. Read the peptide overview and the linked HHS policy for the specific conditions. Checked 5 November 2026. For the single-ingredient condition and its context, see the US policy guide.7